Clinical and prognostic features of plasmacytomas: A multicenter study of Turkish Oncology Group-Sarcoma Working Party

Basit Öğe Kaydı
dc.authoridPehlivan, Mustafa/0000-0002-6692-085X
dc.authoridAtasoy, Beste/0000-0003-1320-9105
dc.authoridorhan, okan/0000-0002-0468-7650
dc.authoridDemiral, Ayse/0000-0003-0388-676X
dc.authorwosidDemiral, Ayşe/Q-1619-2019
dc.authorwosidYAMAN, FULYA/X-5740-2018
dc.authorwosidorhan, okan/KCJ-4491-2024
dc.authorwosidPehlivan, Mustafa/N-3210-2015
dc.authorwosidIsik, Naciye/HGF-1244-2022
dc.authorwosidkilciksiz, Sevil/Y-7790-2018
dc.authorwosidAtasoy, Beste/L-5144-2015
dc.contributor.authorKilciksiz, Sevil
dc.contributor.authorCelik, Omur Karakoyun
dc.contributor.authorPak, Yucel
dc.contributor.authorDemiral, Ayse Nur
dc.contributor.authorPehilvan, Mustafa
dc.contributor.authorOrhan, Okan
dc.contributor.authorTokatli, Fusun
dc.date.accessioned2024-06-12T11:19:59Z
dc.date.available2024-06-12T11:19:59Z
dc.date.issued2008
dc.departmentTrakya Üniversitesien_US
dc.description.abstractTo identify the outcomes of prognostic factors of solitary plasmacytoma mainly treated with local radiotherapy (FIT). The data were collected from 80 patients with solitary plasmacytoma (SP). Forty patients (50.0%) received radiotherapy (FIT) alone while 38 of them (47.5%) were treated with surgery (S) and FIT. The median radiation dose was 46 Gy (range 30-64). The median follow up was 2.41 years (range 0.33-12.33). Ten-year overall survival (OS) and local relapse-free survival (LRFS) were 73% and 94%, respectively. The median progression-free survival (PFS) and multiple myeloma-free survival (MMFS) were 3.5 years and 4.8 years, respectively. On multivariate analyses, the favorable factors were radiotherapy dose of >= 50 Gy and RT + S for PFS and younger age for MMFS. For the patients with medullary plasmacytoma, the favorable factor was younger age for MMFS. RT at >= 50 Gy and RT + S may be favorable prognostic factors on PFS. Younger patients, especially with head-neck lesion and without pre-RT macroscopic tumor, seem to have the best outcome when treated with RT +/- S. Progression to MM remains as the main problem especially for older patients.en_US
dc.identifier.doi10.1002/ajh.21211
dc.identifier.endpage707en_US
dc.identifier.issn0361-8609
dc.identifier.issn1096-8652
dc.identifier.issue9en_US
dc.identifier.pmid18543343en_US
dc.identifier.scopus2-s2.0-51449122235en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage702en_US
dc.identifier.urihttps://doi.org/10.1002/ajh.21211
dc.identifier.urihttps://hdl.handle.net/20.500.14551/25403
dc.identifier.volume83en_US
dc.identifier.wosWOS:000259128600004en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofAmerican Journal Of Hematologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectSolitary Extramedullary Plasmacytomaen_US
dc.subjectRare-Cancer-Networken_US
dc.subjectBone Plasmacytomaen_US
dc.subjectRadiation-Therapyen_US
dc.subjectToxicity Criteriaen_US
dc.subjectNeck Regionen_US
dc.subjectSoft-Tissueen_US
dc.subjectRadiotherapyen_US
dc.subjectMyelomaen_US
dc.subjectHeaden_US
dc.titleClinical and prognostic features of plasmacytomas: A multicenter study of Turkish Oncology Group-Sarcoma Working Partyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu